baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

Cellectis SA/ FR0010425595 /

2024-05-16 9:11:41 AM	Chg. -0.020	Volume	Bid9:13:07 AM	Ask9:12:39 AM	High	Low
2.740EUR	-0.72%	3,818 Turnover: 10,513.525	2.740Bid Size: 554	2.765Ask Size: 750	2.810	2.740

GlobeNewswire 05-13 Allogene Therapeutics Reports First Quarter 2024 Financial Results and Business Update

GlobeNewswire 05-09 Iovance Biotherapeutics Reports First Quarter 2024 Financial Results and Corporate Updates

GlobeNewswire 05-06 Cellectis Announces Completion of the Additional Equity Investment by AstraZeneca

GlobeNewswire 05-02 Cellectis Appoints Arthur Stril as Interim Chief Financial Officer

GlobeNewswire 04-29 Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2023

GlobeNewswire 04-26 Allogene Therapeutics Awarded Grant from the California Institute for Regenerative Medicine to Advan...

GlobeNewswire 04-22 Cellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene Correction and Gene...

GlobeNewswire 04-10 Cellectis Publishes a Novel Intronic Gene Editing Approach For the Treatment of Inborn Metabolic Dis...

GlobeNewswire 04-08 Cellectis Announces Two Poster Presentations on Novel TALEN® Editing Process for Gene Correction and...

GlobeNewswire 03-14 Allogene Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updat...

GlobeNewswire 01-16 Cellectis announces the drawdown of the second tranche of €15 million under the credit facility agre...

GlobeNewswire 01-04 Allogene Therapeutics and Foresight Diagnostics Announce Partnership to Develop MRD-based In-Vitro D...

GlobeNewswire 01-04 Allogene Therapeutics Announces 2024 Platform Vision to Redefine the Future of CAR T Led by ALPHA3, ...

GlobeNewswire 2023-12-22 Cellectis Reports Results from Shareholders Meeting Held on December 22, 2023

GlobeNewswire 2023-12-09 Allogene Therapeutics Presents Comprehensive Safety Data of Proprietary Lymphodepletion Agent ALLO-6...

GlobeNewswire 2023-12-05 Adaptive Biotechnologies and Collaborators to Present More than 30 Abstracts Demonstrating the Actio...

GlobeNewswire 2023-11-17 Cellectis’ Shareholders Meeting to be Held on December 22, 2023

GlobeNewswire 2023-11-15 Cellectis Announces the execution of the Subsequent Investment Agreement with AstraZeneca

GlobeNewswire 2023-11-06 Cellectis Reports Financial Results for Third Quarter and First Nine Months 2023

GlobeNewswire 2023-11-03 Allogene Therapeutics Presents Preclinical Data on a Novel Allogeneic CAR T Product Candidate Target...

GlobeNewswire 2023-11-03 Allogene Therapeutics Presents Preclinical Data on Next Generation Cloak™ and Dagger™ Technologies a...

GlobeNewswire 2023-11-02 Cellectis to Present Preliminary Results of NATHALI_01 and Updated Results of the BALLI_01 Phases I ...

GlobeNewswire 2023-11-02 Allogene Therapeutics Reports Third Quarter 2023 Financial Results and Business Update

GlobeNewswire 2023-11-02 Allogene Therapeutics Announces Poster Presentations at the 65th Annual Meeting of the American Soci...

GlobeNewswire 2023-11-01 Cellectis to Report Third Quarter 2023 Financial Results on November 6, 2023

Cellectis SA/ FR0010425595 /

If you wish to receive reply to your feedback, please provide your email address.